EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Bicaval TricValve Implantation in Patients With Severe Tricuspid Regurgitation

Angel Sánchez-Recalde, Luis M Domínguez-Rodríguez, Liesbeth Rosseel, Luis Nombela-Franco, Roman Pfister, Ignacio Amat-Santos, Christian Butter, Michele Di Mauro, Ignacio Cruz-González, Xavier Freixa, Martin Swaans, Christoph Wilde und 27 weitere

JACC: Cardiovascular Interventions · 2025-08 · 18 (15) · 1913-1924

DOI: 10.1016/j.jcin.2025.06.023 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2025-08. Verfasst von Angel Sánchez-Recalde und 38 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario Ramon y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain. Electronic address: asrecalde@hotmail.com. Hauptthemen laut MEDLINE: Tricuspid Valve Insufficiency, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation, Tricuspid Valve. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Caval valve implantation is currently the only alternative for patients with severe tricuspid regurgitation (TR) who are deemed unsuitable candidates for transcatheter orthotopic therapies. OBJECTIVES: The aim of this study was to assess the efficacy and safety of TricValve system at 1-year follow-up. METHODS: TricBicaval registry is a multicenter registry that retrospectively enrolled all consecutive patients with severe TR treated with TricValve system. RESULTS: Of 204 patients included, 71.1% had renal insufficiency, 87.3% had massive or torrential TR, and 82.4% had TRI-SCOREs of ≥4 points. Intraprocedural success was 96.1%, and clinical success at 30 days was 83%. Functional class significantly improved with 19.8% of patients in NYHA functional class I or II at baseline vs 81.5% (P < 0.001) after a median follow-up period of 8.8 months (Q1-Q3: 1.5-12.3 months). A significant pressure reduction in the inferior vena cava was observed, alongside a marked decrease in signs of right heart failure. Heart failure hospitalizations significantly decreased during follow-up compared with the year preimplantation (60.8 [95% CI: 50.5-73.1] vs 26.9 [95% CI: 19.1-37.8] events per 100 patient-years; P < 0.001). At 1 year, the major adverse event rate was 19.1%, and mortality increased with increasing TRI-SCORE (0-3 points, 6.7% [95% CI: 1.7%-24.6%]; 4 or 5 points, 23.4% [95% CI: 14.4%-36.7%]; ≥6 points, 28.8% [95% CI: 19.8%-40.8%], log-rank P = 0.020). CONCLUSIONS: In this highly comorbid population with severe TR, caval valve implantation using the TricValve system led to significant 1-year clinical improvement, with mortality rates aligned with baseline TRI-SCORE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tricuspid Valve InsufficiencyHeart Valve ProsthesisHeart Valve Prosthesis ImplantationTricuspid ValveVena Cava, InferiorHumansRegistriesFemaleMaleTreatment OutcomeRetrospective StudiesTime FactorsAgedSeverity of Illness IndexRisk FactorsMiddle AgedRecovery of FunctionProsthesis DesignAged, 80 and overHeart Failure

Stichwörter der Autor:innen

TRI-SCOREcaval valve implantationheterotopic tricuspid valve replacementright heart failuretricuspid regurgitation

Autor:innen und Institutionen

  • Hospital Universitario Ramon y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain. Electronic address: asrecalde@hotmail.com.
  • Hospital Universitario Ramon y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.
  • Hartcentrum Aalst, Azorg, Aalst, Belgium.
  • Hospital Universitario Clínico San Carlos, Madrid, Spain.
  • University of Cologne, Faculty of Medicine and University Hospital Cologne, Clinic III for Internal Medicine, Cologne, Germany.
  • Hospital Universitario de Valladolid, Valladolid, Spain; Centro de Investigación Biomédica En Red - Enfermedades Cardiovasculares, Instituto de Salud Carlos III, Madrid, Spain.

Zitieren

APA

Sánchez-Recalde, A., Domínguez-Rodríguez, L. M., Rosseel, L., Nombela-Franco, L., Pfister, R., Amat-Santos, I., Butter, C., Di Mauro, M., Cruz-González, I., Freixa, X., Swaans, M., Wilde, C., Cacela, D., Sarnago, F., Del Trigo, M., Estévez-Loureiro, R., López-Mínguez, J. R., De Torres-Alba, F., Montenegro, M., …, & Zamorano, J. L. (2025). Bicaval TricValve Implantation in Patients With Severe Tricuspid Regurgitation. JACC: Cardiovascular Interventions, 18(15), 1913-1924. https://doi.org/10.1016/j.jcin.2025.06.023

Vancouver

Sánchez-Recalde A, Domínguez-Rodríguez LM, Rosseel L, Nombela-Franco L, Pfister R, Amat-Santos I, et al. Bicaval TricValve Implantation in Patients With Severe Tricuspid Regurgitation. JACC: Cardiovascular Interventions. 2025;18(15):1913-1924. doi:10.1016/j.jcin.2025.06.023

BibTeX
@article{SnchezRecalde2025,
  author = {Sánchez-Recalde, Angel and Domínguez-Rodríguez, Luis M and Rosseel, Liesbeth and Nombela-Franco, Luis and Pfister, Roman and Amat-Santos, Ignacio and Butter, Christian and Di Mauro, Michele and Cruz-González, Ignacio and Freixa, Xavier and Swaans, Martin and Wilde, Christoph and Cacela, Duarte and Sarnago, Fernando and Del Trigo, María and Estévez-Loureiro, Rodrigo and López-Mínguez, José Ramón and De Torres-Alba, Fernando and Montenegro, Marcio and Pérez-Fernández, Ruth and Guzman, Gabriela and Pajín, Fernando and Mylotte, Darren and Pan, Manuel and Kristoff, Cornelis and Carrillo-Suarez, Xavier and de la Torre, José María and Ruiz Quevedo, Valeriano and Salido, Luisa and Parraga, Rocio and Althoff, Jan and Fernández-Cordón, Clara and Guarracini, Stefano and Lopez-Tejero, Sergio and Abdul-Jawad Altisent, Omar and Lautenschläger, Lion and Ramos, Ruben and Puri, Rishi and Zamorano, José L},
  title = {Bicaval TricValve Implantation in Patients With Severe Tricuspid Regurgitation},
  journal = {JACC: Cardiovascular Interventions},
  year = {2025},
  volume = {18},
  number = {15},
  pages = {1913--1924},
  doi = {10.1016/j.jcin.2025.06.023}
}
Kostenlos starten →